News

Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.

Transparent and detailed communication throughout the research process is key for effectively recruiting and retaining patients for clinical trials.

Industry leaders discuss how technology can help companies adapt to the regulatory changes and accomplish their DE&I goals.

Adcetris (brentuximab vedotin) plus lenalidomide and rituximab produced statistically significant and clinically meaningful improvements in overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

Exploring a human-centered, holistic approach for equitable trial outcomes.

The clinical research industry is increasingly leveraging insights, experience, and advanced solutions to better implement diversity and inclusion initiatives.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, speak on what they think the future looks like when it comes to streamlining and improving the clinical trial imaging landscape.

Exploring ways to boost the adoption of eCOA provider-specific libraries—an often-frustrating migration process, but one with significant payoffs in simplified workflows and reduced timelines.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.

Investigational, once-weekly combination shows promise as long-acting oral treatment option for those virologically suppressed with HIV.

Blenrep (belantamab mafodotin) combined with pomalidomide plus dexamethasone showed favorable progression-free survival compared with standard of care in the second-line and later treatment of relapsed or refractory multiple myeloma.

The six steps to designing a successful diversity action plan for a clinical trial protocol.

Why weighing all of the ‘DE&I’ components is critical at site and sponsor levels.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, talk about ways their company has improved efficiency and accuracy in clinical trials for clients such as NCI designated cancer centers.

Despite industry-wide excitement over the involvement of retail pharmacies in clinical research, there is little information currently available on how retail pharmacies are perceived by investigative sites and patients.

Webinar Date/Time: Thu, Mar 28, 2024 12:00 PM EDT

Gilead’s Veklury (remdesivir), a nucleotide analog prodrug, was associated with lower risk of developing long-COVID.

Zilebesiran added to standard of care treatment for mild to moderate hypertension produced a clinically and statistically significant decrease in systolic blood pressure after three months.

Identifying KPIs, benchmarks, key data points, and an actionable plan are all keys to accelerating study start-up cycles.

Elysium Therapeutics’ proprietary O2P is a hydrocodone prodrug for the treatment of moderate-to-severe acute pain.

The FDA previously halted the IOV-LUN-202 trial following reports of a grade 5 serious adverse event that may have been linked to treatment with Iovance Biotherapeutics’ novel tumor infiltrating lymphocyte cell therapy LN-145, which is being evaluated in patients with advanced non–small cell lung cancer.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, provide commentary on current obstacles associated with clinical trials and how their company is addressing them.

While little research on open-cohort designs currently exists, could this design be a solution to challenges currently seen in closed-cohort designs?

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).

Zolgensma (onasemnogene abeparvovec), a one-time gene therapy, showed a clinical benefit for older and heavier patients with spinal muscular atrophy, many of whom were previously treated with another disease-modifying therapy.

With inequalities in palliative care provisions, recent study seeks to create a more equitable, diverse, and inclusive framework based on Patient and Public Involvement.

Data from a pair of Phase III trials indicated a progression-free survival and complete response advantage in favor of Brukinsa in patients with relapsed or refractory chronic lymphocytic leukemia.

Life sciences leaders are overcoming challenges to speed the development, launch, and education of novel medicines for rare diseases.